The DOI matches its Crossref record; 59 of the 60 references it cites were found in a registry or an index.
Anxiolytic Effects in Mice of a Dual Blocker of Fatty Acid Amide Hydrolase and Transient Receptor Potential Vanilloid Type-1 Channels
Open accessAbstract
The endocannabinoid-inactivating enzyme, fatty acid amide hydrolase (FAAH), and the transient receptor potential vanilloid type-1 (TRPV1) channel are new targets for the development of anxiolytic drugs. We studied the effect on anxiety-like behavior in the elevated plus maze of a dual FAAH/TRPV1 blocker, N-arachidonoyl-serotonin (AA-5-HT). In male C57BL/6J mice, acute intraperitoneal administration of AA-5-HT (0.1-2.5 mg/kg) increased both the time spent and the number of entries in the open arm, while being inactive at the highest dose tested (5 mg/kg). AA-5-HT was more potent than selective blockers of FAAH or TRPV1 (URB597 and SB366791, respectively). In male Swiss mice, AA-5-HT had to be administered chronically to observe an anxiolytic effect at an intermediate dose (2.5 mg/kg), the highest dose (5 mg/kg) being anxiogenic, and 1 mg/kg being ineffective. In both strains, the anxiolytic effects of AA-5-HT were paralleled by elevation of brain endocannabinoid levels and were reversed by per se inactive doses of the cannabinoid receptors of type-1 (CB(1)) receptor antagonist AM251, or the TRPV1 agonist, olvanil. Immunohistochemical localization of CB(1) and TRPV1 receptors was observed in mouse prefrontal cortex, nucleus accumbens, amygdala, and hippocampus. Simultaneous 'indirect' activation of CB(1) receptors following FAAH inhibition, and antagonism at TRPV1 receptors might represent a new therapeutic strategy against anxiety.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the anxiolytic agent, diazepam, increases AEA in the amygdala, and bromazepam and buspirone have diminished anxiolytic effects in CB1knockout mice (Micale et al, 2009;Uriguen et al, 2004).”
From Acute stress increases circulating anandamide and other N-acylethanolamines in healthy humans (2012) · cites this paper as Micale et al, 2009
In the citing paper
“the anxiolytic agent, diazepam, increases AEA in the amygdala, and bromazepam and buspirone have diminished anxiolytic effects in CB1knockout mice (Micale et al, 2009;Uriguen et al, 2004).”
From Acute stress increases circulating anandamide and other N-acylethanolamines in healthy humans (2012) · cites this paper as Micale et al, 2009
Citations
Cites
Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor
Devane, W. A., Hanuš, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992) · Science · doi:10.1126/science.1470919 · Cited by 5,633
Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., et al. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00109-d · Cited by 2,913
2-Arachidonoylgylcerol: A Possible Endogenous Cannabinoid Receptor Ligand in Brain
Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A., & Waku, K. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2437 · Cited by 2,196
Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide
Zygmunt, P. M., Petersson, J., Andersson, D. A., Chuang, H.-H., Sørgård, M., Di Marzo, V., Julius, D., & Högestätt, E. D. (1999) · Nature · doi:10.1038/22761 · Cited by 2,142
The endogenous cannabinoid system controls extinction of aversive memories
Marsicano, G., Wotjak, C. T., Azad, S. C., Bisogno, T., Rammes, G., Cascio, M. G., Hermann, H., Tang, J., Hofmann, C., Zieglgänsberger, W., et al. (2002) · Nature · doi:10.1038/nature00839 · Cited by 1,728
Role of Endogenous Cannabinoids in Synaptic Signaling
Freund, T. F., Katona, I., & Piomelli, D. (2003) · Physiological Reviews · doi:10.1152/physrev.00004.2003 · Cited by 1,616
Crawley, J. N., Belknap, J. K., Collins, A. C., Crabbe, J. C., Frankel, W. N., Henderson, N. D., HITZEMANN, R. J., Maxson, S. C., Miner, L. L., Silva, A. J., et al. (1997) · Psychopharmacology · doi:10.1007/s002130050327 · Cited by 1,372
Modulation of anxiety through blockade of anandamide hydrolysis
Kathuria, S., Gaetani, S., Fegley, D., Valiño, F., Duranti, A., Tontini, A., Mor, M., Tarzia, G., Rana, G. L., Calignano, A., et al. (2003) · Nature Medicine · doi:10.1038/nm803 · Cited by 1,293
A Comprehensive Profile of Brain Enzymes that Hydrolyze the Endocannabinoid 2-Arachidonoylglycerol
Blankman, J. L., Simon, G. M., & Cravatt, B. F. (2007) · Chemistry & Biology · doi:10.1016/j.chembiol.2007.11.006 · Cited by 1,177
Huang, S. M., Bisogno, T., Trevisani, M., Al‐Hayani, A., PETROCELLIS, L. D., Fezza, F., Tognetto, M., Petros, T. J., Krey, J. F., Chu, C. J., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.122196999 · Cited by 962
Cristino, L., PETROCELLIS, L. D., Pryce, G., Baker, D., Guglielmotti, V., & Marzo, V. D. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2006.02.074 · Cited by 489
Self-citationGriebel, G., Belzung, C., Perrault, G., & Sanger, D. J. (2000) · Psychopharmacology · doi:10.1007/s002130050038 · Cited by 420
Patel, S., & Hillard, C. J. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.101287 · Cited by 397
Biochemistry and pharmacology of endovanilloids
Starowicz, K., Nigam, S., & Marzo, V. D. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.01.005 · Cited by 381
Marsch, R., Foeller, E., Rammes, G., Bunck, M., Kössl, M., Holsboer, F., Zieglgänsberger, W., Landgraf, R., Lutz, B., & Wotjak, C. T. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.3303-06.2007 · Cited by 359
De Petrocellis, L., Bisogno, T., Davis, J. B., Pertwee, R. G., & Di Marzo, V. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)02082-2 · Cited by 347
Anandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatum
Maccarrone, M., Rossi, S., Bari, M., Chiara, V. D., Fezza, F., Musella, A., Gasperi, V., Prosperetti, C., Bernardi, G., Finazzi‐Agrò, A., et al. (2008) · Nature Neuroscience · doi:10.1038/nn2042 · Cited by 306
Maione, S., Bisogno, T., de Novellis, V., Palazzo, E., Cristino, L., Valenti, M., Petrosino, S., Guglielmotti, V., Rossi, F., & Marzo, V. D. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.093286 · Cited by 299
Self-citationRole in Anxiety Behavior of the Endocannabinoid System in the Prefrontal Cortex
Rubino, T., Realini, N., Castiglioni, C., Guidali, C., Viganò, D., Marras, E., Petrosino, S., Perletti, G., Maccarrone, M., Marzo, V. D., et al. (2007) · Cerebral Cortex · doi:10.1093/cercor/bhm161 · Cited by 295
Self-citationMoreira, F. A., Kaiser, N., Monory, K., & Lutz, B. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.07.005 · Cited by 288
Marzo, V. D., PETROCELLIS, L. D., Fezza, F., Ligresti, A., & Bisogno, T. (2002) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1054/plef.2001.0349 · Cited by 238
van der Stelt, M., Mazzola, C., Esposito, G., Matias, I., Petrosino, S., Filippis, D. D., Micale, V., Steardo, L., Drago, F., Iuvone, T., et al. (2006) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-006-6037-3 · Cited by 223
Self-citationEndocannabinoid mechanisms of pain modulation
Hohmann, A. G., & Suplita, R. L. (2006) · The AAPS Journal · doi:10.1208/aapsj080479 · Cited by 217
Fatty Acids and Immune Responses—A New Perspective in Searching for Clues to Mechanism
Hwang, D. H. (2000) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.20.1.431 · Cited by 205
Maione, S., PETROCELLIS, L. D., de Novellis, V., Moriello, A. S., Petrosino, S., Palazzo, E., Rossi, F., Woodward, D. F., & Marzo, V. D. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707145 · Cited by 200
Self-citationGaal, L. V., Pi‐Sunyer, X., Després, J., McCarthy, C., & Scheen, A. J. (2008) · Diabetes Care · doi:10.2337/dc08-s258 · Cited by 198
Morgese, M. G., Cassano, T., Cuomo, V., & Giuffrida, A. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2007.07.021 · Cited by 195
Evaluation of fatty acid amide hydrolase inhibition in murine models of emotionality
Naidu, P. S., Varvel, S. A., Ahn, K., Cravatt, B. F., Martin, B. R., & Lichtman, A. H. (2007) · Psychopharmacology · doi:10.1007/s00213-006-0689-4 · Cited by 184
Ahluwalia, J., Urbán, L., Bevan, S., & Nagy, I. (2003) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2003.02703.x · Cited by 181
Endogenous Unsaturated C18 N-Acylethanolamines Are Vanilloid Receptor (TRPV1) Agonists
Movahed, P., Jönsson, B., Birnir, B., Wingstrand, J. A., Dyhring, T., Ermund, A., Sterner, O., Zygmunt, P. M., & Högestätt, E. D. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m507429200 · Cited by 172
Arachidonoylserotonin and Other Novel Inhibitors of Fatty Acid Amide Hydrolase
Bisogno, T., Melck, D. J., PETROCELLIS, L. D., Bobrov, М. Y., Gretskaya, N. M., Безуглов, В. В., Sitachitta, N., Gerwick, W. H., & Marzo, V. D. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.8874 · Cited by 171
Starowicz, K., Maione, S., Cristino, L., Palazzo, E., Marabese, I., Rossi, F., de Novellis, V., & Marzo, V. D. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.3258-07.2007 · Cited by 168
Self-citationReceptor-independent actions of cannabinoids on cell membranes: Focus on endocannabinoids
Öz, M. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.09.009 · Cited by 164
Marinelli, S., Marzo, V. D., Florenzano, F., Fezza, F., Viscomi, M. T., van der Stelt, M., Bernardi, G., Molinari, M., Maccarrone, M., & Mercuri, N. B. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301118 · Cited by 155
Marzo, V. D., Starowicz, K., & Cristino, L. (2008) · Current Pharmaceutical Design · doi:10.2174/138161208783330790 · Cited by 153
Self-citationEndocannabinoid System and Synaptic Plasticity: Implications for Emotional Responses
Viveros, M., Marco, E. M., Llorente, R., & López‐Gallardo, M. (2007) · Neural Plasticity · doi:10.1155/2007/52908 · Cited by 151
Dual effect of cannabinoid CB 1 receptor stimulation on a vanilloid VR1 receptor-mediated response
Hermann, H., PETROCELLIS, L. D., Bisogno, T., Moriello, A. S., Lutz, B., & Marzo, V. D. (2003) · Cellular and Molecular Life Sciences · doi:10.1007/s000180300052 · Cited by 144
Lepicard, E. M., Joubert, C., Hagneau, I., Pérez-Díaz, F., & Chapouthier, G. (2000) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(00)00419-6 · Cited by 143
Lafenêtre, P., Chaouloff, F., & Marsicano, G. (2007) · Pharmacological Research · doi:10.1016/j.phrs.2007.09.006 · Cited by 143
Tzavara, E. T., Li, D. L., Moutsimilli, L., Bisogno, T., Marzo, V. D., Phebus, L. A., Nomikos, G. G., & Bruno Giros, A. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.08.019 · Cited by 141
Marinelli, S., Pascucci, T., Bernardi, G., Puglisi‐Allegra, S., & Mercuri, N. B. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300615 · Cited by 137
Impaired cannabinoid receptor type 1 signaling interferes with stress-coping behavior in mice
Steiner, M. A., Wanisch, K., Monory, K., Marsicano, G., Borroni, E., Bächli, H., Holsboer, F., Lutz, B., & Wotjak, C. T. (2007) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500466 · Cited by 130
The Endocannabinoid System and Extinction Learning
Lutz, B. (2007) · Molecular Neurobiology · doi:10.1007/s12035-007-8004-x · Cited by 124
Development of the first potent and specific inhibitors of endocannabinoid biosynthesis
Bisogno, T., Cascio, M. G., Saha, B., Mahadevan, A., Urbani, P., Minassi, A., Appendino, G., Saturnino, C., Martin, B. R., & Razdan, R. K. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2005.12.009 · Cited by 124
Marzo, V. D., Bisogno, T., & PETROCELLIS, L. D. (2007) · Chemistry & Biology · doi:10.1016/j.chembiol.2007.05.014 · Cited by 118
FAAH and anandamide: is 2-AG really the odd one out?
Marzo, V. D., & Maccarrone, M. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.03.001 · Cited by 109
Marzo, V. D., Capasso, R., Matias, I., Aviello, G., Petrosino, S., Borrelli, F., Romano, B., Orlando, P., Capasso, F., & Izzo, A. A. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707682 · Cited by 102
Self-citationAre the anxiogenic effects of yohimbine mediated by its action at benzodiazepine receptors?
Pellow, S., Chopin, P., & File, S. E. (1985) · Neuroscience Letters · doi:10.1016/0304-3940(85)90303-9 · Cited by 95
Effects of the vanilloid agonist olvanil and antagonist capsazepine on rat behaviors
Kasckow, J., Mulchahey, J. J., & Geracioti, T. D. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.10.007 · Cited by 89
Interaction between cannabinoid compounds and diazepam on anxiety-like behaviour of mice
Naderi, N., Haghparast, A., Saber-Tehrani, A. S., Rezaii, N., Alizadeh, A.-M., Khani, A., & Motamedi, F. (2007) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2007.11.001 · Cited by 87
de Lago, E., Petrosino, S., Valenti, M., Morera, E., Ortega‐Gutiérrez, S., Fernández‐Ruíz, J., & Marzo, V. D. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.05.011 · Cited by 86
Self-citationLee, J., Marzo, V. D., & Brotchie, J. M. (2006) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.04.016 · Cited by 73
NewN-Arachidonoylserotonin Analogues with Potential “Dual” Mechanism of Action against Pain
Ortar, G., Cascio, M. G., PETROCELLIS, L. D., Morera, E., Rossi, F., Moriello, A. S., Nalli, M., de Novellis, V., Woodward, D. F., Maione, S., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070678q · Cited by 67
Bisogno, T., & Marzo, V. D. (2007) · Pharmacological Research · doi:10.1016/j.phrs.2007.09.002 · Cited by 59
Consoli, D., Leggio, G. M., Mazzola, C., Micale, V., & Drago, F. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.06.048 · Cited by 53
Self-citationLeggio, G. M., Micale, V., & Drago, F. (2007) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2007.07.003 · Cited by 39
Self-citationKim, S. R., Chung, Y. C., Chung, E. S., Park, K. W., Won, S.-Y., Bok, E., Park, E. S., & Jin, B. K. (2007) · Molecular Neurobiology · doi:10.1007/s12035-007-0030-1 · Cited by 34
USEFULNESS OF ANIMAL MODELS WITH NEWER ANXIOLYTICS
File, S. E. (1992) · Clinical Neuropharmacology · doi:10.1097/00002826-199201001-00273 · Cited by 25
Fowler, C. J., Tiger, G., López-Rodríguez, M. L., Viso, A., Ortega‐Gutiérrez, S., & Ramos, J. A. (2003) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/1475636031000080216 · Cited by 21
Cited by
Sorted by citations
New approaches and challenges to targeting the endocannabinoid system
Marzo, V. D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.115 · Cited by 502
Ligresti, A., PETROCELLIS, L. D., & Marzo, V. D. (2016) · Physiological Reviews · doi:10.1152/physrev.00002.2016 · Cited by 505
Postsynaptic TRPV1 triggers cell type–specific long-term depression in the nucleus accumbens
Grueter, B. A., Brasnjo, G., & Malenka, R. C. (2010) · Nature Neuroscience · doi:10.1038/nn.2685 · Cited by 361
Why do cannabinoid receptors have more than one endogenous ligand?
Di Marzo, V., & De Petrocellis, L. (2012) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2011.0382 · Cited by 290
Best Practice & Research Clinical Endocrinology & Metabolism
Grieb, M. (2009) · Cited by 276
Metadata
- Authors
- Micale, V., Cristino, L., Tamburella, A., Petrosino, S., Leggio, G. M., Drago, F., & Di Marzo, V.
- Affiliations
- University of Catania (IT)
- Institute of Applied Science and Intelligent Systems (IT)
- Istituto di Chimica Biomolecolare (IT)
- Venue
- Neuropsychopharmacology
- Published
- 2008-06-25
- Volume
- 34
- Issue
- 3
- Pages
- 593-606
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W2024922848
- Cited by
- 207
- References
- 60
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 5 · 2023: 3 · 2022: 10 · 2021: 4 · 2020: 12 · 2019: 11 · 2018: 10 · 2017: 12 · 2016: 19 · 2015: 14 · 2014: 23 · 2013: 15 · 2012: 18
- FWCI
- 9.61
- Type
- journal article
- Language
- en
- Open access
- Licence
- other-oa
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- INFM-OAR (INFN Catania) (submittedVersion, other-oa)
- Funders
- Università di Catania
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Life Sciences › Neuroscience › Sensory Systems › Ion Channels and Receptors
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- anxiolytic effects, fatty acid amide hydrolase, TRPV1, endocannabinoids, CB1 receptor, anxiety-like behavior, elevated plus maze, olvanil, URB597, SB366791, prefrontal cortex, amygdala, nucleus accumbens, hippocampus, cannabinoid receptor antagonism
- MeSH terms
- Fatty Acid Amide Hydrolases, Amidohydrolases, Anilides, Animals, Anxiety, Arachidonic Acids, Benzamides, Brain, Capsaicin, Carbamates, Cinnamates, Diazepam, Exploratory Behavior, Male, Mice, Inbred C57BL, Piperidines, Pyrazoles, Serotonin, Anti-Anxiety Agents, Receptor, Cannabinoid, CB1, TRPV Cation Channels, Mice, Cannabinoid Receptor Modulators
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
